XML 19 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2016   34,336,147          
Beginning balance at Dec. 31, 2016 $ 933,562 $ 343 $ 1,238,031 $ (3,838) $ (300,974) $ 21,558 $ 21,558
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Settlement of warrants 323   323        
Equity component of the 2022 Convertible Notes, net of issuance costs and taxes 43,236   43,236        
Equity component of debt repurchase (27,988)   (27,988)        
Shares issued in connection with Endoceutics License Agreement (in shares)   600,000          
Shares issued in connection with Endoceutics License Agreement 13,500 $ 6 13,494        
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares)   (1,366,266)          
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (19,467) $ (14) (19,453)        
Issuance of common stock under employee stock purchase plan (in shares)   120,580          
Issuance of common stock under employee stock purchase plan 1,594 $ 1 1,593        
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares)   392,651          
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (1,267) $ 5 (1,272)        
Non-cash equity based compensation 23,664   23,664        
Unrealized gains (losses) on securities, net of tax (70)     (70)      
Net loss (200,763)       (200,763)    
Ending balance (in shares) at Dec. 31, 2017   34,083,112          
Ending balance at Dec. 31, 2017 $ 787,882 $ 341 1,271,628 (3,908) (480,179) $ 1,136 $ 1,136
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201409Member            
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares) 0            
Issuance of common stock under employee stock purchase plan (in shares)   59,872          
Issuance of common stock under employee stock purchase plan $ 918 $ 1 917        
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares)   463,776          
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings 279 $ 4 275        
Non-cash equity based compensation 19,916   19,916        
Unrealized gains (losses) on securities, net of tax (77)     (77)      
Net loss $ (68,497)       (68,497)    
Ending balance (in shares) at Dec. 31, 2018 34,606,760 34,606,760          
Ending balance at Dec. 31, 2018 $ 741,557 $ 346 1,292,736 (3,985) (547,540)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201409            
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program (in shares) (1,074,800)            
Repurchase and retirement of common stock pursuant to the 2016 Share Repurchase Program $ (13,700)            
Issuance of common stock under employee stock purchase plan (in shares)   185,937          
Issuance of common stock under employee stock purchase plan 1,506 $ 1 1,505        
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (in shares)   281,184          
Net shares issued in connection with the exercise of stock options and vesting of restricted stock units, net of withholdings (1,800) $ 3 (1,803)        
Repurchase of common stock pursuant to the share repurchase program (in shares)   (1,074,800)          
Repurchase of common stock pursuant to the share repurchase program (13,730) $ (11) (13,719)        
Non-cash equity based compensation 19,198   19,198        
Unrealized gains (losses) on securities, net of tax 746     746      
Net loss $ (467,661)       (467,661)    
Ending balance (in shares) at Dec. 31, 2019 33,999,081 33,999,081          
Ending balance at Dec. 31, 2019 $ 279,816 $ 339 $ 1,297,917 $ (3,239) $ (1,015,201)